Chrysin enhances doxorubicin-induced cytotoxicity in human lung epithelial cancer cell lines: The role of glutathione

被引:74
作者
Brechbuhl, Heather M. [3 ]
Kachadourian, Remy [1 ]
Min, Elysia [1 ]
Chan, Daniel
Day, Brian J. [1 ,2 ]
机构
[1] Natl Jewish Hlth, Dept Med, Denver, CO 80206 USA
[2] Univ Colorado, Dept Med, Denver Hlth Sci Ctr, Boulder, CO 80309 USA
[3] Natl Jewish Hlth, Pediat, Denver, CO 80206 USA
关键词
Chrysin; Flavonoids; Glutathione; Multidrug resistance proteins; Adriamycin; Non small cell carcinoma; BREAST TUMOR-CELLS; MULTIDRUG-RESISTANCE; OXIDATIVE STRESS; DRUG-RESISTANCE; L-S; R-BUTHIONINE SULFOXIMINE; HEPATOCELLULAR-CARCINOMA; SIGNALING PATHWAYS; ANTICANCER AGENTS; ELECTRON-TRANSFER; RADICAL FORMATION;
D O I
10.1016/j.taap.2011.08.004
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
We hypothesized that flavonoid-induced glutathione (GSH) efflux through multi-drug resistance proteins (MRPs) and subsequent intracellular GSH depletion is a viable mechanism to sensitize cancer cells to chemotherapies. This concept was demonstrated using chrysin (5-25 mu M) induced GSH efflux in human non-small cell lung cancer lines exposed to the chemotherapeutic agent, doxorubicin (DOX). Treatment with chrysin resulted in significant and sustained intracellular GSH depletion and the GSH enzyme network in the four cancer cell types was predictive of the severity of chrysin induced intracellular GSH depletion. Gene expression data indicated a positive correlation between basal MRP1, MRP3 and MRP5 expression and total GSH efflux before and after chrysin exposure. Co-treating the cells for 72 h with chrysin (5-30 mu m) and DOX (0.025-3.0 mu M) significantly enhanced the sensitivity of the cells to DOX as compared to 72-hour DOX alone treatment in all four cell lines. The maximum decrease in the IC(50) values of cells treated with DOX alone compared to co-treatment with chrysin and DOX was 43% in A549 cells, 47% in H157 and H1975 cells and 78% in H460 cells. Chrysin worked synergistically with DOX to induce cancer cell death. This approach could allow for use of lower concentrations and/or sensitize cancer cells to drugs that are typically resistant to therapy. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 56 条
[1]
Awasthi S, 2003, INT J ONCOL, V22, P713
[2]
Bailey H.H., 1994, J CLIN ONCOL, V12, P194
[3]
Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan [J].
Bailey, HH ;
Ripple, G ;
Tutsch, KD ;
Arzoomanian, RZ ;
Alberti, D ;
Feierabend, C ;
Mahvi, D ;
Schink, J ;
Pomplun, M ;
Mulcahy, RT ;
Wilding, G .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (23) :1789-1796
[4]
L-S,R-buthionine sulfoximine:: historical development and clinical issues [J].
Bailey, HH .
CHEMICO-BIOLOGICAL INTERACTIONS, 1998, 112 :239-254
[5]
Glutathione Transport Is a Unique Function of the ATP-binding Cassette Protein ABCG2 [J].
Brechbuhl, Heather M. ;
Gould, Neal ;
Kachadourian, Remy ;
Riekhof, Wayne R. ;
Voelker, Dennis R. ;
Day, Brian J. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (22) :16582-16587
[6]
Brunati A. M., FREE RADIC RES, V44, P363
[7]
Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes [J].
Calcagno, A. M. ;
Fostel, J. M. ;
To, K. K. W. ;
Salcido, C. D. ;
Martin, S. E. ;
Chewning, K. J. ;
Wu, C-P ;
Varticovski, L. ;
Bates, S. E. ;
Caplen, N. J. ;
Ambudkar, S. V. .
BRITISH JOURNAL OF CANCER, 2008, 98 (09) :1515-1524
[8]
Clinical studies of reversal of drug resistance based on glutathione [J].
Calvert, P ;
Yao, KS ;
Hamilton, TC ;
O'Dwyer, PJ .
CHEMICO-BIOLOGICAL INTERACTIONS, 1998, 112 :213-224
[9]
CIRCU ML, FREE RADIC BIOL MED, V48, P749
[10]
Transport of glutathione and glutathione conjugates by MRP1 [J].
Cole, Susan P. C. ;
Deeley, Roger G. .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2006, 27 (08) :438-446